MALVERN, Pa., May, 2022 – DSG, Inc., a global leader of eClinical software solutions and services for the life sciences industry has announced continued record growth and profitability for 2022 with its complete integrated EDC solutions. DSG has successfully increased revenue and has contributed to numerous decentralized global studies.
DSG has been actively assisting clinical research across start-up biotech and small to large Pharmaceuticals, supporting and enriching all phases of the clinical trials process. DSG has focused on strengthening the decentralized clinical study capabilities with its clients and partners while innovating participant registry functionality. In addition, DSG is ensuring clinical trial success through its innovative eCaseLink Platform with a series of modules to help clinical researchers and sites approach the decentralized clinical model.
“DSG leads the industry with its award-winning eCaseLink Platform. DSG was first to bring the clinical trial experience to all research settings including onsite and remote capabilities. We have partnered with multiple teams to enhance our platform and bring quality trial management software to clinical research” said Tony Varano, Chief Executive Officer at DSG. “Despite the current economic slowdown, DSG remains committed to providing value to our customers and innovating new solutions around the clinical trial research lifecycle.”
DSG, Inc. is a leading global eClinical provider with a unified suite of innovative technology solutions for the global clinical research community. DSG's eClinical software platform provides competitive advantage that is cost-effective and quickest to build. DSG’s award-winning eCaseLink solutions are used in thousands of clinical trials around the globe.